ABIVAX Signs Agreement with the Finlay Institute to Commercialise Meningococcal and Typhoid Vaccines in Asia and Latin America

November 12, 2014 ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, today announced that it has signed an agreement with The Finlay Institute, Havana, Cuba, that will allow it to commercialise vaccines against typhoid, meningococcus, and leptospirosis, in Asian and Latin American markets. Under the terms of the agreement, ABIVAX will gain exclusive …

Download Ebook: Five Vaccines Missing in Asia

Asia is home to 4,299 billion people. Growing trends of infectious disease and pandemic outbreaks in Asia have heightened the measures taken to combat these epidemics. However, these battles are far from over; although reports show reduction in certain infectious diseases, progress is still slow. Vaccines are increasingly important in preventing these outbreaks. In this E-book, we have identified the …

Download: How to advance regulatory convergence in Asia

At this years World Vaccine Congress Asia Wang Der-Yuan, Division of Research and Analysis, (TFDA) Department of Health, Republic of China delivered the presentation: Advancing Regulatory Convergence in Asia with International Standards. Some of the points explored in this presentation include: Prophylactic Vaccines Vaccine needs in Asia Current regulatory process for vaccines Regulatory process of NRA How to ensure safety …

Download – Investing in Asia: Enabling vaccine industry success

Interested in entering Asia’s vaccine market? Learn how to succeed from Dr. Matthias Bucerius, Head of Sales Asia, Pharm Chemicals Soltuions, Merck Millipore, Germany. Dr. Bucerius joined the in-house Consulting Department of Merck KGaA in 2004. During his time working out of Darmstadt, he supported projects for Merck’s Chemicals and Pharma Business Sectors and Central Functions. In 2007, Dr. Bucerius …